Tumor necrosis factor (TNF) is being utilized as an antineoplastic agent for the treatment of
patients with locally advanced solid tumors. However, its role in cancer therapy is debated …

PURPOSE:: Renal cell carcinoma (RCC) has traditionally been staged using a purely
anatomical staging system. Although current staging systems provide good prognostic …

VELCADE®(bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson &
Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ) is a first-in-class …

Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated
for single-agent use in the treatment of patients with multiple myeloma who have received at …

Nuclear factor-κB (NF-κB) is a signal transcription factor that has emerged as an important
modulator of altered gene programs and malignant phenotype in development of cancer …

Background There is increasing evidence that solid cancers contain cancer-initiating cells
(CICs) that are capable of regenerating a tumor that has been surgically removed and/or …

▪ Abstract The proteasome, a multicatalytic proteinase complex, is responsible for the
majority of intracellular protein degradation. Pharmacologic inhibitors of the proteasome …

Renal cell carcinoma (RCC) is the most lethal of the common urologic malignancies, with
approximately 40% of patients eventually dying of cancer progression. Approximately one …

This review discusses 26 new anticancer drugs approved by the FDA in the past decade.
Based on their targets, these anticancer agents can be divided into three groups. First group …

Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular
carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of …